4D Molecular Therapeutics
FDMT • NASDAQ
4D Molecular Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO David H. Kirn, with a market cap of $502.3M.
Market Cap$502.3M
Employees171.0
CEODavid H. Kirn
CountryUnited States of America
Healthcare
Biotechnology
Next EarningsMay 7, 2026 · In 3 weeksQ1 2026
Financials
4D Molecular Therapeutics FAQ
Common questions about 4D Molecular Therapeutics
4D Molecular Therapeutics is scheduled to report earnings for Q1 2026 on May 7, 2026. Analysts estimate revenue of $3.1M.
4D Molecular Therapeutics has approximately 171 employees.